Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Exelixis: Defying Corona Bear Market Expectations (NASDAQ:EXEL)
11:45am, Monday, 15'th Jun 2020
Exelixis recently presented robust Phase 3 data for CheckMate-9ER, which galvanized a substantial rally. Riding strong fundamental development, Exelixis posted
20,735 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by AlphaCrest Capital Management LLC
08:03am, Sunday, 14'th Jun 2020
AlphaCrest Capital Management LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange
Hedge Funds Going Back and Forth About Exelixis, Inc. (EXEL)
02:15pm, Friday, 12'th Jun 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filing
Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-01, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with
Exelixis Inc (EXEL) CEO Michael Morrissey Presents at Goldman Sachs Global Healthcare Conference (Transcript)
05:44am, Thursday, 11'th Jun 2020
Exelixis Inc (NASDAQ:EXEL) Goldman Sachs Global Healthcare Conference June 10, 2020 2:10 PM ET Company Participants Michael Morrissey - President & CEO Conf
Exelixis, Inc. (NASDAQ:EXEL) Holdings Decreased by Sowell Financial Services LLC
06:16am, Wednesday, 10'th Jun 2020
Sowell Financial Services LLC lessened its stake in Exelixis, Inc. (NASDAQ:EXEL) by 34.6% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The insti
Physicians’ Education Resource® Launches “Oncology NOW” Webcast Series
12:00am, Friday, 05'th Jun 2020
Physicians’ Education Resource® Launches “Oncology NOW” Webcast Series
Exelixis (EXEL) Down 11.5% Since Last Earnings Report: Can It Rebound?
03:31pm, Thursday, 04'th Jun 2020
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
08:05pm, Wednesday, 03'rd Jun 2020
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in June:
Edited Transcript of EXEL earnings conference call or presentation 5-May-20 9:00pm GMT
06:59am, Tuesday, 02'nd Jun 2020
Q1 2020 Exelixis Inc Earnings Call
Oppenheimer Maintains Outperform on Exelixis, Raises Price Target to $32
03:44pm, Monday, 01'st Jun 2020Biotech ETFs Are Soaring. These Four Are Still Worth Considering.
12:00pm, Monday, 01'st Jun 2020
Investors have been bullish on biotech, in the hope that companies will soon come up with a treatment, cure, or vaccine for Covid-19. But there’s more to biotech than the coronavirus, and even thoug
Is There An Opportunity With Exelixis, Inc.'s (NASDAQ:EXEL) 49% Undervaluation?
10:58am, Thursday, 28'th May 2020
Today we will run through one way of estimating the intrinsic value of Exelixis, Inc. (NASDAQ:EXEL) by taking the...
3 Charts That Suggest Biotech Stocks Are Headed Higher
05:30pm, Wednesday, 20'th May 2020
Breakouts beyond key levels of resistance suggest that the bulls are in control of the momentum in the biotech sector.
Patent Filings Roundup: The Return of the Founder, Retailers Target Wireless LLC, European NPE Revives 2G/3G Patent Wars
04:15pm, Wednesday, 20'th May 2020
There were only 16 new patent filings at the Patent Trial and Appeal Board (PTAB)—all inter partes reviews (IPRs)—this week, with a whopping 70 new district court complaints filed.
